Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Ga-68-CXCR4.
- Who it may be relevant to
- Registry conditions: Indolent B-Cell Non-Hodgkin Lymphoma. Basic parameters: 20 years — 100 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Taiwan
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Ga-68-CXCR4 PET/CT in Detecting, Evaluating Response to Treatment, and Monitoring Risk of Aggressiveness of Indolent B-cell Lymphoma
Overview
This study explores the efficacy of Ga-68-PentixaFor PET/CT in detecting, assessing treatment response, and monitoring the risk of aggressiveness in indolent B-cell lymphoma. The background introduces CXCR4 and discusses its role in cancer research. Currently, FDG-PET is the primary imaging tool for lymphoma staging, but it lacks diagnostic accuracy for low-grade lymphomas. Ga-68-PentixaFor PET demonstrates promising detection capabilities across various lymphomas, suggesting its potential as a superior imaging modality for low-grade lymphomas.
Interventions
- Drug Ga-68-CXCR4
Ga-68-CXCR4 for PET/CT procedure in Indolent B-cell Lymphoma
Primary outcome measures
- Performance of Ga-68-CXCR4 PET/CT in indolent B cell lymphoma [Time frame: up to 24 months]
Secondary outcome measures (3)
- Ga-68-CXCR4 compared to F-18-FDG PET/CT [Time frame: up to 24 months]
- Clinical impact of Ga-68-CXCR4 compared to F-18-FDG PET/CT [Time frame: up to 24 months]
- Prognostic value of Ga-68-CXCR4 PET/CT scan [Time frame: up to 36 months]
Eligibility criteria
Inclusion criteria
- The pathological diagnosis is slow-growing lymphoma, such as: marginal-zone B-cell lymphoma, Waldenstrom macroglobulinemia lymphocytic lymphoma, CLL/SLL, mantle cell lymphoma.
- Have undergone or planned to undergo FDG PET scan for indications including initial staging, therapeutic response evaluation, or follow-up examinations within 3 to 6 months in the clinical observation group.
- Able to lie flat for at least 30 minutes.
- Signing the subject consent form.
- ECOG grade 0-2.
- The timing of F-18-FDG usage in this trial follows the "Lymphoma Treatment Principles" of our institution.
Exclusion criteria
- Pregnant woman
- Severe renal impairment (eGRF< 30ml/min)
- Known or suspected allergy to radiopharmaceuticals
- Concurrent or previous diagnosis of malignancies other than lymphoma
- Inability to undergo the necessary PET scan procedure
- Refusal or unwillingness to sign the informed consent form
- Severe medical conditions (severe disabilities, mental disorders)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
Taiwan · 1 center
- Koo Foundation Sun Yat-Sen Cancer Center — Taipei
Identifiers
NCT: NCT06461182 · KF-CXCR4-001